ArticleInternational journal of clinical and experimental pathology2018
High EGFL6 expression is associated with clinicopathological characteristics in colorectal cancer.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- EGFL6 is a novel HER3 ligand, inducing HER3/integrin heterodimers to induce pERK centrosomal deposition and therapeutic resistance.Neoplasia (New York, N.Y.) · 2025Article
- Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration.Scientific reports · 2025Article
- EGFL6 promotes endometrial cancer cell migration and proliferation.Gynecologic oncology · 2024Article
- Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.Gynecologic oncology · 2023Article
- Development and Validation of a Three-Gene Prognostic Signature Based on Tumor Microenvironment for Gastric Cancer.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the expression levels of EGFL6 in colorectal cancer and the association between EGFL6 and its clinicopathological parameters in patients. Immunohistochemistry assay was used to detect the expression levels of EGFL6 in cancer tissues of 42 colorectal cancer cases and corresponding adjacent normal tissues. The associations between protein expression levels of EGFL6 and the clinicopathological features, such as age, gender, smoking status, drinking status, TNM stage, Tumor T status, lymph node status, distant metastasis, and tumor diameter were also analyzed. We measured the plasma EGFL6 levels of colorectal cancer patients by using a commercial enzyme-linked immunosorbent assay. The positive rate of EGFL6 in cancer tissues was significantly higher than that of cancer-adjacent tissues (P < 0.05). Correlation was found between the protein expression of EGFL6 and the TNM stage (P < 0.05), the tumor T status (P < 0.05), distant metastasis (P < 0.05) and tumor diameter (P < 0.05). The plasma EGFL6 levels were significantly higher in patients with colorectal cancer than in healthy controls (P < 0.001). Moreover, plasma EGFL6 levels were significantly higher in the patients with higher TNM stage (P = 0.024), tumor T status (P = 0.021), distant metastasis (P < 0.001), and tumor diameter (P = 0.049). Therefore, these results demonstrated that EGFL6 expression was correlated with the genesis and development of colorectal cancer.
Indexed as
Identifiers
31949676PMC6963056W3027798139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.